Chargement en cours...
Aspergillosis in a Patient Receiving Temozolomide for the Treatment of Glioblastoma
Leukopenia and selective CD4+ lymphopenia represent major adverse events associated with the use of temozolomide (TMZ), an oral alkylating agent incorporated in the treatment of glioblastoma (GBM). The increased risk of opportunistic infections, including those caused by Pneumocystis jiroveci and cy...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
S. Karger AG
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3764971/ https://ncbi.nlm.nih.gov/pubmed/24019780 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000354429 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|